S-3 EX-FILING FEES 0001157075 N/A N/A 0001157075 1 2025-09-15 2025-09-15 0001157075 2 2025-09-15 2025-09-15 0001157075 3 2025-09-15 2025-09-15 0001157075 2025-09-15 2025-09-15 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-3

PharmaCyte Biotech, Inc.

Table 1: Newly Registered and Carry Forward Securities

                                           
Line Item Type   Security Type   Security Class Title   Notes   Fee Calculation
Rule		   Amount Registered   Proposed Maximum Offering
Price Per Unit		   Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                           
Newly Registered Securities
Fees to be Paid   Equity   Common stock, $0.0001 par value per share, underlying shares of Series C convertible preferred stock   (1)   Other   10,500,000   $ 1.05   $ 11,025,000.00   0.0001531   $ 1,687.93
Fees to be Paid   Equity   Common stock, $0.0001 par value per share, underlying Investor Warrants   (2)   Other   10,500,000     1.05     11,025,000.00   0.0001531     1,687.93
Fees to be Paid   Equity   Common stock, $0.0001 par value per share, underlying Placement Agent Warrants   (3)   Other   560,000   $ 1.05   $ 588,000.00   0.0001531   $ 90.02
                                           
Total Offering Amounts:   $ 22,638,000.00         3,465.88
Total Fees Previously Paid:                
Total Fee Offsets:               0.00
Net Fee Due:             $ 3,465.88

__________________________________________
Offering Note(s)

(1) This Registration Statement registers 21,560,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of PharmaCyte Biotech, Inc. (the “Company”), issuable upon (i) the conversion of shares of Series C convertible preferred stock, (ii ) exercise of warrants (the “Investor Warrants”) that were sold in a private placement and (iii) exercise of warrants that were issued pursuant to the engagement letter between the Company and GP Nurmenkari Inc. as consideration for placement agent services in connection with the Offering (the “Placement Agent Warrants”).

Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee on the basis of the average of the high and low prices of the Common Stock as reported on The Nasdaq Capital Market on September 12, 2025, a date within five business days prior to filing this Registration Statement.

(2) See footnote 1
(3) See footnote 1